Table 1 Patient characteristics
N | Descriptive, median (IQR) or n (%) | Not achieved CD4/CD8 ratio < 1 (N = 606) | Achieved CD4/CD8 ratio ≥ 1 (N = 194) | p-value | |
|---|---|---|---|---|---|
Gender, n (%) | 800 | < 0.001 | |||
Male | 533 (66.63) | 439 (72.44) | 94 (48.45) | ||
Female | 267 (33.38) | 167 (27.56) | 100 (51.55) | ||
Age at start ARV | 800 | 32.3 (27.4–37.5) | 31.8 (26.7–37.1) | 33.7 (28.6–38.5) | 0.006 |
Pre-cART HIV-RNA level (log10 copies/mL) | 800 | 4.8 (4.39–5.24) | 4.83 (4.44–5.25) | 4.67 (4.18–5.2) | 0.003 |
Pre-cART CD4 count (cells/mm3) | 799 | 206 (102–291) | 193 (80–282) | 229 (170–316) | 0.0001 |
Pre-cART CD8 count (cells/mm3) | 769 | 853 (611–1190) | 890 (616–1219) | 818 (596–1109) | 0.16 |
Pre-ART CD4/CD8 ratio | 769 | 0.22 (0.12–0.32) | 0.20 (0.10–0.30) | 0.28 (0.18–0.39) | < 0.001 |
CDC grading, n (%) | 790 | 0.045 | |||
A | 466 (58.99) | 338 (56.71) | 128 (65.98) | ||
B | 223 (28.23) | 174 (29.19) | 49 (25.26) | ||
C | 101 (12.78) | 84 (14.09) | 17 (8.76) | ||
Route of transmission, n (%) | 800 | 0.002 | |||
Heterosexual | 433 (54.13) | 305 (50.33) | 128 (65.98) | ||
MSM/bisexual | 280 (35) | 233 (38.45) | 47 (24.23) | ||
IDU | 6 (0.75) | 5 (0.83) | 1 (0.52) | ||
Others | 4 (0.5) | 4 (0.66) | 0 (0) | ||
Unknown | 77 (9.63) | 59 (9.74) | 18 (9.28) | ||
Months since cART start to first virological suppression | 7 (4–35) | 7 (3–34) | 9 (4–38) | 0.51 | |
Duration of cART (years) | 800 | 8.9 (5.2–13.7) | 7.0 (4.2–12.1) | 13.5 (9.3–16.7) | < 0.001 |
Duration of viral suppression (years) | 800 | 6.08 (2.97–10.75) | 4.91 (2.26–9.12) | 10.77 (7.49–12.74) | < 0.001 |
CD4/CD8 ratio at first viral suppression, median (IQR) | 800 | 0.42 (0.27–0.56) | 0.38 (0.24–0.5) | 0.54 (0.42–0.69) | < 0.001 |
CD4/CD8 ratio at first viral suppression, n (%) | 800 | < 0.001 | |||
< 0.3 | 224 (28.00) | 209 (34.49) | 15 (7.73) | ||
0.30–0.45 | 228 (28.50) | 182 (30.03) | 46 (23.71) | ||
> 0.45 | 348 (43.50) | 215 (35.48) | 133 (68.56) | ||
Positive HBsAg, n (%) | 784 | 130/784 (16.58) | 108/592 (18.24) | 22/192 (11.46) | 0.028 |
Positive anti-HCV Ab, n (%) | 796 | 66/796 (8.29) | 50/602 (8.31) | 16/194 (8.25) | 0.980 |
Baseline ARV regimen, n (%) | 800 | < 0.001 | |||
PI-based regimen | 272 (34) | 178 (29.37) | 94 (48.45) | ||
NNRTI-based regimen | 509 (63.63) | 411 (67.82) | 98 (50.52) | ||
INSTI-based regimen | 19 (2.38) | 17 (2.81) | 2 (1.03) |